CHRS Collaborates
Coherus and Zumutor Biologics start a Phase 1 study evaluating ZM008 in combination with LOQTORZI
CHRS - Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)- First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor -